Molecular and Genetic Regulation of Craniofacial Development

颅面发育的分子和遗传调控

基本信息

  • 批准号:
    8103255
  • 负责人:
  • 金额:
    $ 37.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-25 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Craniofacial anomalies account for nearly one-third of all birth defects and are a severe cause of morbidity and mortality in infants. In spite of their prevalence, the underlying genetic and molecular mechanisms causing most craniofacial defects remain largely unknown. The long-term goal of the proposed studies is to define the molecular and genetic pathways that control craniofacial development for the purpose of regeneration and repair, tissue engineering, and the diagnosis of and intervention into congenital craniofacial birth defects. Specifically, this application is focused on the identification of the transcriptional pathways and mechanisms involved in craniofacial development. Recent work has identified a novel genetic model for Pierre Robin Sequence (PRS) in mice. PRS occurs in about 1 in every 800 live births and is characterized by small lower jaw, improperly positioned tongue and posterior cleft of the palate, which can result in upper airway obstruction and feeding difficulties. Previously, it was thought that PRS occurred as a result of environmental factors that restrict outgrowth of the mandible, but it is now quite clear that this sequence also has an undefined genetic component(s). Mice that carry one mutant allele of Dlx5/6 locus and one mutant copy of the Mef2c allele die at birth from craniofacial defects resembling PRS. The Dlx5/6 locus encodes two Distal-less related homeobox transcription factors, while the Mef2c locus encodes a MADS box transcription factor. In addition to their genetic interaction, MEF2C and Dlx5 cooperate to induce a robust synergistic transcriptional response. The hypotheses underlying this proposal are that Dlx5/6 and MEF2C form a transcriptional complex downstream of endothelin receptor signaling, that this complex is essential for the activation of a subset of genes that are required for craniofacial development, and that mutations or aberrant expression of Dlx5/6-MEF2C target genes contributes to craniofacial anomalies such as PRS. To address these hypotheses, three specific aims are proposed. Aim 1 will define the physical and functional interaction between Dlx5 and MEF2C and how this results in transcriptional activation. The goal is to define the transcriptional mechanisms that control gene expression during craniofacial development. Aim 2 will analyze the craniofacial defects in Mef2c-Dlx5/6 double heterozygotes in detail. The goal is to identify possible cellular mechanisms underlying the mandible and palate phenotypes in double heterozygotes to understand how these processes control palate closure and jaw growth. Aim 3 will identify upstream regulators of Mef2c transcription in craniofacial mesenchyme and will determine whether Mef2c is a direct target of the endothelin signaling pathway, using a transgenic mouse approach. The goals are to place Mef2c into a transcriptional pathway and to identify the immediate transcriptional effectors of endothelin signaling in craniofacial development. PUBLIC HEALTH RELEVANCE: Craniofacial anomalies, which account for nearly one third of all birth defects and are estimated to occur in 1 every 300 live births, are a severe cause of morbidity and mortality in infants. In spite of the prevalence of craniofacial birth defects, the underlying genetic and molecular mechanisms causing these anomalies remain largely unknown. The proposed studies will contribute to the understanding of the molecular and genetic mechanisms controlling craniofacial development, which is essential for determining how to reactivate or modulate these programs for the purpose of regeneration and repair, tissue engineering, and the diagnosis of and intervention in craniofacial birth defects.
描述(由申请人提供):颅面畸形占所有出生缺陷的近三分之一,是婴儿发病和死亡的严重原因。尽管它们普遍存在,但导致大多数颅面缺陷的潜在遗传和分子机制在很大程度上仍然未知。拟议研究的长期目标是确定控制颅面发育的分子和遗传途径,用于再生和修复,组织工程以及先天性颅面出生缺陷的诊断和干预。具体而言,本申请集中在颅面发育中所涉及的转录途径和机制的鉴定上。最近的工作已经确定了一种新的遗传模型皮埃尔罗宾序列(PRS)在小鼠中。每800名活产婴儿中约有1名发生PRS,其特征是下颌小,舌头位置不当和腭后裂,这可能导致上呼吸道阻塞和喂养困难。以前,人们认为PRS是由于限制下颌骨生长的环境因素而发生的,但现在很清楚,该序列也具有不确定的遗传成分。携带Dlx 5/6基因座的一个突变等位基因和Mef 2c等位基因的一个突变拷贝的小鼠在出生时死于类似PRS的颅面缺陷。Dlx 5/6基因座编码两个远端较少相关的同源盒转录因子,而Mef 2c基因座编码MADS盒转录因子。除了它们的遗传相互作用之外,MEF 2C和Dlx 5合作以诱导稳健的协同转录应答。该提议的基础假设是Dlx 5/6和MEF 2C形成内皮素受体信号传导下游的转录复合物,该复合物对于颅面发育所需的基因子集的激活是必需的,并且Dlx 5/6-MEF 2C靶基因的突变或异常表达有助于颅面异常,例如PRS。为了解决这些假设,提出了三个具体目标。目的1将定义Dlx 5和MEF 2C之间的物理和功能相互作用,以及这如何导致转录激活。目的是确定颅面发育过程中控制基因表达的转录机制。目的2详细分析Mef 2c-Dlx 5/6双杂合子的颅面缺损。我们的目标是确定潜在的细胞机制的下颌骨和腭表型在双杂合子,以了解这些过程如何控制腭闭合和颌骨生长。目的3将确定Mef 2c转录的颅面间充质的上游调控,并将确定是否Mef 2c是内皮素信号通路的直接目标,使用转基因小鼠的方法。目标是将Mef 2c纳入转录途径,并确定颅面发育中内皮素信号传导的直接转录效应子。 公共卫生关系:颅面异常占所有出生缺陷的近三分之一,估计每300名活产中就有1例发生颅面异常,是婴儿发病和死亡的一个严重原因。尽管颅面出生缺陷普遍存在,但导致这些异常的潜在遗传和分子机制在很大程度上仍然未知。拟议的研究将有助于了解控制颅面发育的分子和遗传机制,这对于确定如何重新激活或调节这些程序以实现再生和修复,组织工程以及颅面出生缺陷的诊断和干预至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian L Black其他文献

Brian L Black的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian L Black', 18)}}的其他基金

Project 3: Control of cardiac transcription by MEF2 and myocardin
项目3:MEF2和心肌素控制心脏转录
  • 批准号:
    10471991
  • 财政年份:
    2019
  • 资助金额:
    $ 37.09万
  • 项目类别:
Project 3: Control of cardiac transcription by MEF2 and myocardin
项目3:MEF2和心肌素控制心脏转录
  • 批准号:
    10006190
  • 财政年份:
    2019
  • 资助金额:
    $ 37.09万
  • 项目类别:
Project 3: Control of cardiac transcription by MEF2 and myocardin
项目3:MEF2和心肌素控制心脏转录
  • 批准号:
    10245031
  • 财政年份:
    2019
  • 资助金额:
    $ 37.09万
  • 项目类别:
NAVBO Workshops at Vascular Biology 2017
2017 年血管生物学 NAVBO 研讨会
  • 批准号:
    9331793
  • 财政年份:
    2017
  • 资助金额:
    $ 37.09万
  • 项目类别:
NAVBO Workshops at Vascular Biology 2014
2014 年血管生物学 NAVBO 研讨会
  • 批准号:
    8785754
  • 财政年份:
    2014
  • 资助金额:
    $ 37.09万
  • 项目类别:
Molecular and Genetic Regulation of Craniofacial Development
颅面发育的分子和遗传调控
  • 批准号:
    8499043
  • 财政年份:
    2009
  • 资助金额:
    $ 37.09万
  • 项目类别:
Molecular and Genetic Regulation of Craniofacial Development
颅面发育的分子和遗传调控
  • 批准号:
    7792319
  • 财政年份:
    2009
  • 资助金额:
    $ 37.09万
  • 项目类别:
Molecular and Genetic Regulation of Craniofacial Development
颅面发育的分子和遗传调控
  • 批准号:
    7938865
  • 财政年份:
    2009
  • 资助金额:
    $ 37.09万
  • 项目类别:
Molecular and Genetic Regulation of Craniofacial Development
颅面发育的分子和遗传调控
  • 批准号:
    8291115
  • 财政年份:
    2009
  • 资助金额:
    $ 37.09万
  • 项目类别:
Regulation of cardiac gene expression by MEF2-Myocardin transcription complexes
MEF2-Myocardin 转录复合物对心脏基因表达的调节
  • 批准号:
    8590744
  • 财政年份:
    2008
  • 资助金额:
    $ 37.09万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.09万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了